Reassessment of sst3 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5

Neuroendocrinology

Volumn 96, Issue 4, 2012, Pages 301-310

  Lupp, Amelie ^a   Nagel, Falko ^a   Doll, Christian ^a   Röcken, Christoph ^b   Evert, Matthias ^c   Mawrin, Christian ^d   Saeger, Wolfgang ^e   Schulz, Stefan ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e Marienkrankenhaus Hamburg ^*  (Germany)

Author keywords

Antibody; Neuroendocrine tumors; Pituitary; Somatostatin; Somatostatin receptor

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY UMB 5; SOMATOSTATIN RECEPTOR 3; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; SOMATOSTATIN RECEPTOR;

ADENOHYPOPHYSIS; ADRENAL CORTEX; ADRENAL MEDULLA; ADSORPTION; ARTICLE; CELL POPULATION; CELLULAR DISTRIBUTION; DEGLYCOSYLATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR WEIGHT; NEUROENDOCRINE TUMOR; PANCREAS ISLET; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CELL STRAIN HEK293; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; RABBIT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PITUITARY GLAND; RABBITS; RECEPTORS, SOMATOSTATIN;

EID: 84871608713     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000337659     Document Type: Article

References (46)

1. Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G: Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Dig Liv Dis 2004; 36(suppl 1):S8-S16.
2. Ben-Shlomo A, Melmed S: Pituitary soma-tostatin receptor signaling. Trends Endocri-nol Metab 2010; 21:123-133.
3. De Martino MC, Hofland LJ, Lamberts SW: Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Bra in Res 2010; 182: 255-280.
4. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, Arnold R: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002; 50:52-60.
5. Oberg KE, Reubi JC, Kwekkeboom DJ, Kren-ning EP: Role of somatostatins in gastroen-teropancreatic neuroendocrine tumor development and therapy. Gastroenterol 2010; 139: 742-753.
6. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C: Antitumor effects of so-matostatin. Mol Cell Endocrinol 2008; 286: 230-237.
7. Msaouel P, Galanis E, Koutsilieris M: Soma-tostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investigat Drugs 2009; 18: 1297-1316.
8. Lu HT, Salamon H, Horuk R: The biology and function of somatostatin receptors. Expert Opin Ther Targets 2001; 5:613-623.
9. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W: Regulation and function of so-matostatin receptors. J Neurochem 2004; 89: 1057-1091.
10. Tulipano G, Schulz S: Novel insights in somatostatin receptor physiology. Eur J Endocrinol 2007; 156:S3-S11.
11. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10:1688-1696.
12. War SA, Somvanshi RK, Kumar U: Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta 2011; 1813: 390-402.
13. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A: Somatostatin inhibits tumor angiogenesis and growth via so-matostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen activated protein kinase activities. Endocrinology 2003; 144:1574-1584.
14. Liew C W, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwarz JR, Schulz S, Buck F, Serrano L, Richter D, Krei-enkamp HJ: Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett 2009; 583: 49-54.
15. Tulipano G, Stumm R, Pfeiffer M, Kreien-kamp HJ, Höllt V, Schulz S: Differential ß-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004; 279: 21374-21382.
16. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC: Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. PNAS 2006; 103:16436-16441.
17. Ginj M, Zhang H, Eisenwiener K P, Wild D, Schulz S, Rink H, Cescato JC, Reubi JC, Maecke R: New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 2008; 14:2019-2027.
18. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S: Reassessment of sst2 so-matostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal a nt ibody UMB-1. J Clin Endocrinol Metab 2008; 93: 4519-4524.
19. Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S: Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphoryla-tion. Mol Endocrinol 2010; 24: 436-446.
20. Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S: Reassessment of sst5 somatosta-tin receptor expression in normal and neo-plastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendo-crinolog y 2011; 94255-264.
21. Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H: Somatostatin receptor subt y pes in hu man pheochromoc y-toma: subcellular expression pattern and functional relevance for octreotide scintig-raphy. J Clin Endocrinol Metab 2001; 88: 5150-5157.
22. Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V: Immu-nohistochemical determination of five so-matostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 2000; 6:1865-1874.
23. Lupp A, Danz M, Müller D: Morphology and cytochrome P450 isoforms expression in precision-cut rat liver slices. Toxicol 2001; 161: 53-66.
24. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreac-tive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-140.
25. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S: Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009; 94: 654-661.
26. Portela-Gomes GM, Stridsberg M, Grime-lius L, Öberg K, Janson ET: Expression of five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000; 8:126-132.
27. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S: Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol 2008; 68: 850-857.
28. Nishioka H, Tamura K, Iida H, Kutsukake M, Endo A, Ikeda Y, Haraoka J: Co-expression of somatostatin receptor subtypes and estrogen receptor-a mRNAs by non-functioning pituitary adenomas in young patients. Mol Cell Endocrinol 2011; 331: 73-78.
29. Van Op den Bosch J, Van Nassauw L, Lanter-mann K, Van Marck E, Timmermans JP: Effect of intestinal inflammation on the cell-specific expression of somatostatin receptor subtypes in the murine ileum. Neurogastro-enterol Motil 2007; 19: 596-606.
30. Van Op den Bosch, Lantermann K, Torfs P, Van Marck E, Van Nassauw L, Timmermans JP: Distribution and expression levels of somatostatin and somatostatin receptors in the ileum of normal and acutely Schistosoma mansoni-infected SSTR2 knockout/lacZ knockin mice. Neurogastroenterol Motil 2008; 20: 798-807.
31. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J, Jorgensen JOL: Expression of soma-tostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 2001; 24:430-437.
32. Reubi JC, Waser B, Schaer JC, Laissue JA: So-matostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-select ive liga nds. Eur J Nucl Med 2001; 28: 836-846.
33. Taboada GF, Luque RM, Bastos W, Gui-marães RFC, Marcondes JB, Chimelli LMC, Fontes R, Mata PJP, Niemeyer Filho P, Car-valho DP, Kineman RD, Gadelha MR: Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007; 156:65-74.
34. Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M: Expression of somatostatin receptor subtypes in human pituitary adenomas-immunohistochemical studies. En-dokrynol Polska 2009; 60: 240-251.
35. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y: Differential expression of so-matostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-se-creting pituitary tumors and silent cortico-t roph adenomas. Endocr J 2009; 56: 579-584.
36. Chanson P, Brochier S: Non-functioning pituitary adenomas. J Endocrinol Invest 2005; 28: 93-99.
37. Jaffe CA: Clinically non-functioning pitu-itar y adenoma. Pituitary 2006; 9: 317-321.
38. Korbonits M, Carlsen E: Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Hormone Res 2009; 71(suppl 2):123-130.
39. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bi-anchi A, Schmid HA, Scanarini M, Pontecor-vi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007; 14:91-102.
40. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, degli Uberti EC: Effect of everolimus on cell viability in nonfunction-ing pituitary adenomas. J Clin Endocrinol Metab 2010; 95: 968-976.
41. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, Kulkarni H, Haugvik SV, Hommann M, Baum RP: Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011, DOI: 10.1007/s00259-011-1846-5.
42. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C, Höllt V: Immunocytochem-ical detection of somatostatin receptors sst1, sst2A, sst2B and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998; 4: 2047-2052.
43. Schulz S, Schmitt J, Quednow C, Roessner A, Weise W: Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gyn Oncol 2002; 84:235-240.
44. Schulz S, Schmitt J, Weise W: Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gyn Oncol 2003; 89:385-390.
45. Li M, Li W, Min HJ, Yao QZ, Chen CY, Fisher WE: Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004; 119: 130-137.
46. Mawrin C, Schulz S, Pauli SU, Treuheit T, Diete S, Dietzmann K, Firsching R, Schulz S, Höllt V: Differential expression of sst1, ss-t2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas. J Neuropathol Exp Neurol 2004; 63: 13-19.